MICROPORT (00853) shares surged 5.95% in early trading on Monday following the announcement of groundbreaking clinical trial results for its Firehawk® coronary drug-eluting stent system. The results, published in the prestigious New England Journal of Medicine and presented at the European Society of Cardiology Congress 2025, demonstrate a significant advancement in cardiovascular treatment.

The TARGET-FIRST clinical study revealed that for low-risk acute myocardial infarction patients who achieved complete revascularization with the Firehawk® stent, the duration of dual antiplatelet therapy can be reduced from 12 months to just one month. This reduction does not increase ischemic risks and, notably, leads to a 54% decrease in bleeding complications. The study's simultaneous publication in a top-tier journal and presentation at a major academic conference underscores its potential to rapidly change global clinical practice.

Investors are reacting positively to the news, recognizing the Firehawk® stent's unique clinical value and its potential to address the "high quality-economic efficiency-accessibility" challenge in medical devices. With the Firehawk® stent already introduced in 67 countries across multiple continents, MICROPORT is now poised to focus on commercialization and promotion in the North American market, potentially opening up significant growth opportunities for the company.